9 November 2016 – WTO TRIPS Council – UNCTAD’s statement on the Report of the UN High-Level Panel on Access to Medicines
On Wednesday, 9 November 2016, the United Nations Conference on Trade and Development (UNCTAD) delivered the following statement at the World Trade Organization’s (WTO) TRIPS Council’s discussions of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines. UNCTAD informed WTO members that the agency had recently recommended to Secretary-General Ban Ki-moon to consider endorsement of the Report of the High Level Panel.
9 November 2016 – WTO TRIPS Council – India’s intervention on the Report of the UN High-Level Panel on Access to Medicines
On Wednesday, 9 November 2016, India delivered the following statement at the World Trade Organization’s (WTO) TRIPS Council’s discussions of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines.
Agenda item 13: the United Nations Secretary-General’s High Level Panel Report on Access to Medicines
Statement by India.
Thank you Chairman.
At the outset, I would like to thank delegations of Brazil, China and South Africa who are also co-sponsors of this agenda item.
9 November 2016 – WTO TRIPS Council – WHO’s intervention on the Report of the UN High-Level Panel on Access to Medicines
On Wednesday, 9 November 2016, the World Health Organization (WHO) delivered the following statement at the World Trade Organization’s (WTO) TRIPS Council’s discussions of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines.
COUNCIL FOR TRIPS
8-9 NOVEMBER 2016
WHO STATEMENT
13. THE UNITED NATIONS SECRETARY-GENERAL’S HIGH LEVEL PANEL REPORT ON ACCESS TO MEDICINES
Thank you very much for giving WHO the opportunity to share our feedback on the Report of the High-Level Panel on Access to Medicines.
9 November 2016 – WTO TRIPS Council – Brazil’s intervention on the Report of the UN High-Level Panel on Access to Medicines
On 9 November 2016, the World Trade Organization’s (WTO) TRIPS Council held discussions on the United Nations Secretary-General’s High-Level Panel Report on Access to Medicines (UN HLP). These timely WTO discussions on the UN HLP germinated from a 27 October 2016 request by Brazil, China, India and South Africa requesting the WTO Secretariat to place a dedicated agenda item for consideration at the 8-9 November 2016 session of the TRIPS Council entitled “the United Nations Secretary-General’s High-Level Panel Report on Access to Medicines.”
WTO TRIPS Council – Brazil, China, India and South Africa request discussion of the UN High-Level Panel on Access to Medicines
On Thursday, 27 October 2016, Brazil, China, India and South Africa submitted a communication (IP/C/W/619) to the World Trade Organization (WTO) requesting the WTO Secretariat to “place a dedicated agenda item for consideration at the 8-9 November 2016 session of the TRIPS Council entitled “the United Nations Secretary-General’s High-Level Panel Report on Access to Medicines.” In the WTO submission, Brazil, China, India and South Africa enclosed the entire Final Report of the UN Secretary-General’s High-Level Panel on Access to Continue Reading
Extending Bayh-Dole March-in rights
In a recent exchange with Senator Durbin, NIH Director Francis Collins expressed his concern that the NIH would alienate potential collaborators if the NIH applied the march-in remedy to address excessive prices of drugs. Continue Reading
2016: Kite Pharma, KEI Comments on NIH Proposed Exclusive License for Cancer Treatment
Today, KEI submitted comments to the Notice published in the Federal Register on October 5, 2016, entitled “Prospective Grant of Exclusive Patent License: Development of Anti-CD70 Chimeric Antigen Receptors for the Treatment of CD70 Expressing Cancers.” KEI’s comments addressed issues with the NIH’s processes for granting exclusive licenses, and transparency in those licenses, resulting data, trials, pricing, and revenue.
Continue ReadingKite Pharma Press Releases & News Stories Related to Relationship with National Cancer Institute
Kite Pharma is a California-based biopharmaceutical company working on various types of cell therapies for the treatment of cancer, in a bid to become the first pharmaceutical firm to gain successful FDA approval for this new class of cancer treatment.
Kite closely collaborates with the National Cancer Institute, which conducted significant early research into the forms of cell therapies that Kite is seeking to commercialize. NCI conducts clinical trials under Cooperative Research and Development Agreements (CRADAs) with Kite, and additionally has granted exclusive licenses on over a dozen patents to Kite on the same technologies.
Continue Reading17 October 2016: USTR Ambassador Michael Froman’s reflections on the United Nations High-Level Panel on Access to Medicines
On Monday morning, 17 October 2016, the United States Trade Representative, Michael Froman, delivered a lecture at the Graduate Institute entitled, The WTO in a Time of Change: Some Reflections.
WIPO General Assembly 2016: Opening Statement of Knowledge Ecology International
On October 4th, 2016, Knowledge Ecology International (KEI) delivered this opening statement on the occasion of the Fifty-Sixth Series of Meetings of the Assemblies of the Member States of the World Intellectual Property Organization (WIPO).
KEI General Statement – WIPO General Assembly – 2016October 4th, 2016
Thank you Chair for providing Knowledge Ecology International (KEI) the opportunity to speak today.